Absci/$ABSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Ticker
$ABSI
Sector
Primary listing
Employees
157
Headquarters
Website
Absci Metrics
BasicAdvanced
$562M
-
-$0.94
2.02
-
Price and volume
Market cap
$562M
Beta
2.02
52-week high
$6.33
52-week low
$2.01
Average daily volume
5M
Financial strength
Current ratio
4.387
Quick ratio
3.772
Long term debt to equity
2.142
Total debt to equity
4.275
Interest coverage (TTM)
-311.21%
Profitability
EBITDA (TTM)
-103.73
Gross margin (TTM)
-1,634.75%
Net profit margin (TTM)
-2,737.94%
Operating margin (TTM)
-2,812.74%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-31.26%
Return on equity (TTM)
-57.39%
Valuation
Price to revenue (TTM)
109.201
Price to book
2.77
Price to tangible book (TTM)
3.69
Price to free cash flow (TTM)
-5.889
Free cash flow yield (TTM)
-16.98%
Free cash flow per share (TTM)
-0.638
Growth
Revenue change (TTM)
27.32%
Earnings per share change (TTM)
1.45%
3-year revenue growth (CAGR)
-4.91%
3-year earnings per share growth (CAGR)
-8.83%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Bulls say / Bears say
Absci’s July 2025 underwritten public offering and ATM facility raised approximately $64 million, extending its cash runway into the first half of 2028 and securing funding for its AI-driven therapeutic pipeline. (GlobeNewswire)
The ongoing first-in-human Phase 1 trial of ABS-101 is on track with an interim data readout expected in the second half of 2025, marking Absci’s transition to a clinical-stage company and de-risking its lead program. (GlobeNewswire)
A September 11 collaboration with Oracle Cloud Infrastructure and AMD provides bare-metal GPU access with inter-GPU latencies as low as 2.5 µs, reducing computation overhead and accelerating Absci’s AI-powered biologics design cycles. (GlobeNewswire)
Second-quarter 2025 revenue plunged 53.8% to $0.6 million from $1.3 million a year earlier, reflecting the volatility of partnership-driven income and challenges scaling commercial revenue. (GlobeNewswire)
R&D expenses rose 34% year-over-year to $20.5 million in Q2 2025, driving a higher cash burn rate that could pressure financial resources if operational milestones slip. (GlobeNewswire)
Net loss widened to $30.6 million in Q2 2025 from $24.8 million in Q2 2024, underlining persistent unprofitability as the company invests heavily ahead of potential revenue inflections. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Absci News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Absci stock?
Absci (ABSI) has a market cap of $562M as of October 07, 2025.
What is the P/E ratio for Absci stock?
The price to earnings (P/E) ratio for Absci (ABSI) stock is 0 as of October 07, 2025.
Does Absci stock pay dividends?
No, Absci (ABSI) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Absci dividend payment date?
Absci (ABSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Absci?
Absci (ABSI) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.